img description

MorEx Development Partners LLP (“MorEx”) was formed in 2008 as a partnership between Morvus Technology Limited (“Morvus”) and an investor group led by Stephens Investments of Little Rock, Arkansas, (“Stephens”).

MorEx was formed to drive the development of MTL-005, taking it from late pre-clinical into first-in-man clinical trials. Morvus originally licensed the background intellectual property to MTL-005 from the world-renowned Brookhaven National Laboratory. Further discovery and preclinical work was undertaken via a Cooperative Research and Development Agreement (CRADA), leading to additional intellectual property in relation to formulation and clinical use.